M
Mesoblast Limited D
D
MESO
16.810
USD
-0.27
(-1.60%)
مغلق
حجم التداول
4,115
الربح لكل سهم
-1
العائد الربحي
-
P/E
-20
حجم السوق
2,156,613,399
الأخبار المقالات
العنوان: Mesoblast Limited
القطاع: Healthcare
الصناعة: Biotechnology
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.